Market revenue in 2023 | USD 15.4 million |
Market revenue in 2030 | USD 43.0 million |
Growth rate | 15.7% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 81.17% in 2023. Horizon Databook has segmented the Japan mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
Japan has a large number of ongoing clinical research studies. The rising prevalence of cancer, aging population, and increasing disease burden are further expected to stimulate demand for novel diagnosis and treatment methods. Japan also holds a major position in miRNA research owing to increasing regulatory support and government funding in research.
For instance, Grants-in-Aid for Scientific Research, a funding wing of Japan Society for the Promotion of Science, intended to provide financial support for scientific research. Under this program, various research studies related to miRNA applications are being conducted.
For instance, a group of researchers evaluated the different levels of microRNAs associated with Ischemic Heart Disease (IHD) in blood between the Austrian and Japanese populations. A difference in miRNA level was found between the countries' populations, and as a result, it was concluded that mortality from IHD is significantly lower in Japan compared to Austria.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into Japan mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account